TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32390703

Group type: EXPERIMENTAL
Intervention: LKB1/STK11 gene sequencing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Other gene sequencing (APC, AXIN2, BMPR1A, EPCAM, MLH1, MLH3, MSH2, MSH6, MUTYH, PMS1, PMS2, PTEN, SMAD4)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Colorectal hamartoma polyps with LKB1/STK11 mutations
Number of subjects: 20
Study: 36088901

Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (1,000 mg in total)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (500 mg in total)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (counterpart saline)
Number of subjects: 56
Study: 33456356

Group type: EXPERIMENTAL
Intervention: Three-miRNA signature (hsa-miR-139-3p, hsa-miR-760, hsa-miR-7-5p)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: High-risk score based on three-miRNA signature
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Three-miRNA signature
Number of subjects: 344

Group type: COMPARATOR
Intervention: hsa-miR-139-3p
Number of subjects: 344

Group type: COMPARATOR
Intervention: hsa-miR-7-5p and hsa-miR-760
Number of subjects: 344
Study: 32885274

Group type: EXPERIMENTAL
Intervention: glasdegib + LDAC
Number of subjects: 116

Group type: COMPARATOR
Intervention: LDAC alone
Number of subjects: 116
Study: 34645657

Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 220
Study: 32703974

Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training (HIFT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Walking at 60% of heart rate reserve (WALK)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CON) - physically inactive reading a book
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Trail Making Test
Number of subjects: 35
Study: 34914232

Group type: EXPERIMENTAL
Intervention: Microsurgical varicocelectomy followed by oral administration of Danhong Tongjing Prescription (DTP) for 90 days
Number of subjects: 68

Group type: COMPARATOR
Intervention: Microsurgical varicocelectomy (control group)
Number of subjects: 68
Study: 33043615

Group type: EXPERIMENTAL
Intervention: Pelvic external beam radiotherapy (EBRT) with or without vault brachytherapy (VB) boost; 79% recommended for Stage IIIA cases, 77% for IIIC1 cases.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pelvic EBRT combined with chemotherapy; 61% for Stage IIIA cases, 88% for IIIC1 cases.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Vault brachytherapy (VB); recommended when pelvic EBRT was offered for 4 of the 5 case scenarios.
Number of subjects: 65
Study: 32075677

Group type: EXPERIMENTAL
Intervention: VITAL Start (video intervention)
Number of subjects: 892

Group type: COMPARATOR
Intervention: Standard-of-care pre-ART counseling
Number of subjects: 892
Study: 36498393

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 0
Study: 34509031

Group type: EXPERIMENTAL
Intervention: Family Start up Program (FSP)
Number of subjects: 1701

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 1701
Study: 35166029

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser + topical triamcinolone (TA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intralesional triamcinolone (TA)
Number of subjects: 22
Study: 33640890

Group type: EXPERIMENTAL
Intervention: Low-dose hydroxychloroquine therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33318523

Group type: EXPERIMENTAL
Intervention: Moderate-intensity PA intervention (at least 1 hour/week of supervised strenuous activity)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both dietary and PA interventions
Number of subjects: 234

Group type: COMPARATOR
Intervention: Isocaloric dietary intervention mainly based on plant-foods
Number of subjects: 234

Group type: COMPARATOR
Intervention: General recommendations on healthy dietary and PA patterns
Number of subjects: 234
Study: 616382121

Group type: EXPERIMENTAL
Intervention: Motor imagery practice (MI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 34352792

Group type: EXPERIMENTAL
Intervention: Dental varnish containing casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) and 5% fluoride (MI varnish; GC, Japan)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dental varnish with 5% fluoride alone (NUPRO White; Dentsply, USA)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dental varnish containing CPP‐ACP and 5% fluoride (MI varnish; GC, Japan)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 32907559

Group type: EXPERIMENTAL
Intervention: Collaborative care model involving co-location of psychologists and psychiatrists in GP practices.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Collaborative care model with experienced mental health specialists.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Collaborative care model.
Number of subjects: 24
Study: 35225079

Group type: EXPERIMENTAL
Intervention: Dual-task training with progression from variable to fixed priority
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dual-task training with variable priority
Number of subjects: 60
Study: 33039952

Group type: EXPERIMENTAL
Intervention: DMB (vitamin D3 1000 IU/d, magnesium 150 mg/d, vitamin B12 500 mcg/d)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (no DMB)
Number of subjects: 43
Study: 35289741

Group type: EXPERIMENTAL
Intervention: Co-ordinated multidisciplinary care, patient-relevant sedation plans, assessment of ventilation parameters, higher trigger for extubation readiness test, spontaneous breathing trial on low levels of respiratory support
Number of subjects: 8843

Group type: EXPERIMENTAL
Intervention: Co-ordinated multidisciplinary care
Number of subjects: 8843

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 8843
Study: 32182889

Group type: EXPERIMENTAL
Intervention: Lifestyle patterns identified as 'Discretionary consumption and TV'
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: Lifestyle patterns identified as 'Fruit, vegetables and outdoor'
Number of subjects: 710
Study: 34446469

Group type: EXPERIMENTAL
Intervention: Convalescent plasma combined with standard of care
Number of subjects: 483

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 483
Study: 33470039

Group type: EXPERIMENTAL
Intervention: Moderate value of rCBVmean in long-term survivors (LTSs)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: rCBVmean in short-term survivors (STS)
Number of subjects: 99
Study: 32209931

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 20
Study: 35033180

Group type: EXPERIMENTAL
Intervention: One dose of PCV at 6 weeks with a booster at 9 months (1+1 schedule)
Number of subjects: 784

Group type: COMPARATOR
Intervention: Three primary doses of PCV at 6, 10, and 14 weeks (3+0 schedule)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: Co-administration of PCV with yellow fever vaccine at 9 months
Number of subjects: 784
Study: 33164984

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) treatment (1 g/m2)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: ALL subtypes (T cell ALL [T-ALL], B cell ALL [B-ALL] with TCF3-PBX1 or ETV6-RUNX1 fusions)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: ALL subtypes (hyperdiploid and BCR-ABL like)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Folate pathway genes (SLC19A1, ABCC1, ABCC4, FPGS, MTHFD1)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Multivariable model including ALL subtype, SLC19A1/(ABCC1 + ABCC4) transporter ratio, MTX infusion time, FPGS mRNA expression, and MTX systemic clearance
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Longer infusion time (24 h vs. 4 h)
Number of subjects: 388
Study: 34052278

Group type: EXPERIMENTAL
Intervention: Specific Carbohydrate Diet (SCD)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Mediterranean Diet (MD)
Number of subjects: 194
Study: 37584752

Group type: EXPERIMENTAL
Intervention: Head-lift exercise (HLE)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 32873926

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) - alternate fast days at 25% energy requirements and ad libitum feed days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) - 75% energy requirements daily
Number of subjects: 46
Study: 36166026

Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy (4.5 mg/kg intravenously every 3 weeks)
Number of subjects: 585

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (intravenously every 3 weeks)
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy
Number of subjects: 585

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 585
Study: 34035414

Group type: EXPERIMENTAL
Intervention: Continuous apical negative ultrasonic irrigation (CANUI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Positive pressure irrigation (PPI)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Passive ultrasonic irrigation (PUI)
Number of subjects: 120
Study: 33957881

Group type: EXPERIMENTAL
Intervention: Alternate-day oral administration of S-1 (80 mg/m2/day) for 4 days a week (Group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 2-week oral administration of S-1 (80 mg/m2/day) followed by 1 week of rest (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Group B (2-week S-1 followed by 1 week rest)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group A (alternate-day S-1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All patients (n=93)
Number of subjects: 90
Study: 32007688

Group type: EXPERIMENTAL
Intervention: PCDD/Fs exposure (fg TEQ/bw/day)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Serum PCDD/Fs (fg TEQ/g lipid)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Mediation analysis of urinary 8-OHdG
Number of subjects: 423
Study: 36501109

Group type: EXPERIMENTAL
Intervention: Multinutrient formula containing B group vitamins, Bacopa monniera and Ginkgo biloba
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Multinutrient formula
Number of subjects: 141
Study: 33522931

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg oral arm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo arm
Number of subjects: 48
Study: 35444166

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Number of subjects: 60
Study: 34559992

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on day 1, followed by 5 mg/kg per day on days 2-5)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 1400
Study: 32771909

Group type: EXPERIMENTAL
Intervention: Women's Health CoOp (WHC) intervention
Number of subjects: 120
Study: 36272210

Group type: EXPERIMENTAL
Intervention: GlobalConsent (adapted web-based sexual violence prevention program)
Number of subjects: 793

Group type: COMPARATOR
Intervention: Attention control (web-based program)
Number of subjects: 793
Study: 33011836

Group type: EXPERIMENTAL
Intervention: Chest X-ray imaging for nasogastric tube verification
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Patient-related predictor regression model (sex, age, body mass index)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Environmental factor regression model (guidewire presence)
Number of subjects: 215
Study: 35617329

Group type: EXPERIMENTAL
Intervention: Group-based exercise
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 120
Study: 33812497

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks
Number of subjects: 307

Group type: COMPARATOR
Intervention: Chemotherapy (mFOLFOX6 or FOLFIRI)
Number of subjects: 307
Study: 36163868

Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Idelalisib plus rituximab or bendamustine plus rituximab (investigator's choice)
Number of subjects: 250
Study: 34487977

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 6

Group type: COMPARATOR
Intervention: High-carbohydrate diet (HCD)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Habitual diet (HD)
Number of subjects: 6
Study: 33932744

Group type: COMPARATOR
Intervention: Chain pharmacies
Number of subjects: 921

Group type: COMPARATOR
Intervention: Independent pharmacies
Number of subjects: 921

Group type: COMPARATOR
Intervention: Pharmacies in Southern states
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Overall pharmacies
Number of subjects: 921
Study: 33119613

Group type: EXPERIMENTAL
Intervention: Rintatolimod treatment in the Target Subset (n = 75)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study: 33401124

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stress management training (SMT)
Number of subjects: 60
Study: 35170124

Group type: EXPERIMENTAL
Intervention: Opium tincture
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 204

Group type: COMPARATOR
Intervention: Heroin
Number of subjects: 204
Study: 34115305

Group type: EXPERIMENTAL
Intervention: Elevated O3 (E‐O3)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ambient air (AA)
Number of subjects: 8
Study: 32242399

Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion (HPM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 36
Study: 33562177

Group type: EXPERIMENTAL
Intervention: Knee flexion angle of 110 degrees
Number of subjects: 16

Group type: COMPARATOR
Intervention: Knee flexion angles of 90, 130, and 150 degrees
Number of subjects: 16
Study: 32532280

Group type: EXPERIMENTAL
Intervention: Secondary distribution with monetary incentives
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Secondary distribution with monetary incentives plus peer referral
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard secondary distribution
Number of subjects: 300
Study: 36310098

Group type: EXPERIMENTAL
Intervention: Short‐Medium‐Long intervals (SML‐INT; n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Long intervals (L‐INT; n = 7)
Number of subjects: 14
Study: 35998966

Group type: EXPERIMENTAL
Intervention: Lay-delivered Behavioural Activation (Do More, Feel Better; DMFB)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Clinician-delivered Behavioural Activation (BA)
Number of subjects: 288
Study: 35029706

Group type: EXPERIMENTAL
Intervention: CBD 300 mg
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 32538277

Group type: EXPERIMENTAL
Intervention: Therapeutic ingredients identified in the Very Early Rehabilitation in Speech (VERSE) trial
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cumulative intervention intensity (CII) calculated by counting identified therapeutic ingredients
Number of subjects: 53
Study: 32586585

Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Direct Oral Anticoagulants (DOAC)
Number of subjects: 402
Study: 35637624

Group type: EXPERIMENTAL
Intervention: 15 mg CBD
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 300 mg CBD
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1500 mg CBD
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 34239138

Group type: EXPERIMENTAL
Intervention: Efruxifermin 28 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Efruxifermin 50 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Efruxifermin 70 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32051304

Group type: EXPERIMENTAL
Intervention: DECIDE intervention (clinical decision support system)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 134
Study: 34798295

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (MNTX) administered perioperatively
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 34825104

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) applied in the first 10–15 min of each Physical Education class, twice a week for 16 weeks, with 14 to 20 all-out bouts intervals and a 2:1 work to rest ratio.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual programmed Physical Education classes (control group).
Number of subjects: 300
Study: 35964210

Group type: EXPERIMENTAL
Intervention: Robotic-assisted gait training (30 minutes) + conventional physical therapy (30 minutes)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional physical therapy (60 minutes)
Number of subjects: 21
Study: 33690826

Group type: EXPERIMENTAL
Intervention: Modified audio-tactile performance technique with braille (ATPb)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Audio-tactile performance technique (ATP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Audio method (AM)
Number of subjects: 90
Study: 32943843

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg, then 2 mg/kg/h, IV)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 90
Study: 34416020

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34134738

Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 107
Study: 34970862

Group type: EXPERIMENTAL
Intervention: Dietary intervention groups (5 different groups) for weight maintenance for 6 months
Number of subjects: 0
Study: 32818325

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention adapted for SAD (MBI-SAD)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cognitive behaviour group therapy (CBGT)
Number of subjects: 97
Study: 36306478

Group type: EXPERIMENTAL
Intervention: Yoga intervention group (10 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20
Study: 33172346

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - performed the intervention programme for 18 sessions over 6 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control Group (CG) - continued their normal physical activities
Number of subjects: 35
Study: 35469428

Group type: EXPERIMENTAL
Intervention: LT4 oral solution (Tirosint®‐SOL) 600 mcg taken 15 minutes before a high-fat high-calorie meal
Number of subjects: 36

Group type: COMPARATOR
Intervention: LT4 oral solution (Tirosint®‐SOL) 600 mcg taken 30 minutes before a high-fat high-calorie meal
Number of subjects: 36
Study: 34582369

Group type: EXPERIMENTAL
Intervention: Linagliptin (5 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34059935

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied to the ipsilateral hemisphere
Number of subjects: 35

Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation (TMS) applied to the contralateral hemisphere
Number of subjects: 35
Study: 32447494

Group type: EXPERIMENTAL
Intervention: 3D endoscopic ear surgery (EES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D endoscopic ear surgery (EES)
Number of subjects: 0
Study: 35007127

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) 0.8 mg/m2 intravenously on day 1 and 0.5 mg/m2 on days 8 and 15 of a 28-day cycle.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) followed by hematopoietic stem-cell transplantation
Number of subjects: 48
Study: 34143803

Group type: EXPERIMENTAL
Intervention: Nguvu intervention (8 weekly sessions delivered by lay refugee incentive workers)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 311
Study: 35128870

Group type: EXPERIMENTAL
Intervention: Biao-Ben acupoints group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conventional acupoint group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 120
Study: 32029252

Group type: EXPERIMENTAL
Intervention: Intravascular imaging
Number of subjects: 11264

Group type: COMPARATOR
Intervention: No imaging
Number of subjects: 11264
Study: 34057543

Group type: EXPERIMENTAL
Intervention: Riboflavin (400 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Phenazopyridine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (Thiamine)
Number of subjects: 84
Study: 33499921

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu (XFZY), 3 times per day for 3 menstrual cycles
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo, 3 times per day for 3 menstrual cycles
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu (XFZY)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Xuefu Zhuyu (XFZY) and Placebo
Number of subjects: 248
Study: 32043545

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco users who also smoke cigarettes
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Waterpipe tobacco users who smoke less than all day
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Younger age at starting smoking
Number of subjects: 510

Group type: COMPARATOR
Intervention: No association found
Number of subjects: 510
Study: 35367245

Group type: EXPERIMENTAL
Intervention: STRIP intervention group (heart-healthy diet with low SAFA and cholesterol, biannual counselling from 7 months to 20 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 34212187

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 2092

Group type: COMPARATOR
Intervention: Standard 12-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor
Number of subjects: 2092
Study: 32408065

Group type: EXPERIMENTAL
Intervention: 2.45 GHz Wi-Fi (max psSAR10g of 6.4 mW/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham signals
Number of subjects: 34
Study: 35339652

Group type: EXPERIMENTAL
Intervention: Massage chair used twice a day for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group educated about lifestyle modification
Number of subjects: 80